OrbiMed’s Mirum Pharmaceuticals MIRM Stock Holding History

OrbiMed’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-521,891	Closed	-$11K	–	127
2022 Q3	$11K	Buy	521,891 +242,391	+87%	+$5.84M	0.2%	82
2022 Q2	$5.44K	Buy	279,500 +252,500	+935%	+$5.96M	0.1%	109
2022 Q1	$595K	Buy	+27,000	New	+$551K	0.01%	140
2020 Q1	–	Sell	-71,300	Closed	-$1.75M	–	156
2019 Q4	$1.75M	Buy	+71,300	New	+$760K	0.03%	121

Other funds holding MIRM

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

RVM

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed's MIRM Position: Q4 2022 in Review

OrbiMed sold out of Mirum Pharmaceuticals (MIRM) in Q4 2022, closing a stake of 521,891 shares — an estimated $11K sold.

OrbiMed first reported a position in MIRM in Q4 2019 and held it in 4 quarters. The position peaked at $1.75M in Q4 2019. 104 funds tracked by Wall St. Rank hold MIRM as of Q4 2022.

OrbiMed reported no remaining Mirum Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
OrbiMed sold 521,891 Mirum Pharmaceuticals shares in Q4 2022, an estimated $11K.
OrbiMed first reported a position in Mirum Pharmaceuticals in Q4 2019 and held it in 4 quarters.
OrbiMed's Mirum Pharmaceuticals position peaked at $1.75M in Q4 2019.
104 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2022.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.